Preservation of Skeletal Muscle Mass with SGLT2 inhibitors under Nutritional Assessment and/or Intervention in Underweight HFpEF (The PRESERVE-HF trial)

未提供0 个研究点目标入组 36 人开始时间: 待定

适应症

试验速览

暂无简介。

•Participants must meet all of the following criteria
•Patients aged 20 years or older
•Patients diagnosed with heart failure with preserved ejection fraction (HFpEF)
•Patients with a body mass index (BMI) of less than 22 kg/m2
•Patients who have provided written informed consent to participate in the study

•Participants will be excluded from the study if they meet any of the following criteria:
•Patients with significant left-sided valvular disease, severe coronary artery disease, decompensated heart failure, or cardiomyopathy
•Patients with comorbid conditions unrelated to heart failure that are expected to significantly limit life expectancy to less than one year
•Patients with implanted medical devices such as pacemakers or implantable cardioverter defibrillators (ICDs)
•Patients who are currently taking SGLT2 inhibitors
•Patients with type 1 diabetes mellitus
•Patients with eGFR less than 20 mL/min/1.73 m2
•Patients for whom empagliflozin is contraindicated according to the drug information
•Patients whose dietary intake (amount or content) is judged by the investigator to be unstable or to vary significantly from day to day
•Patients who are currently participating in another interventional study
•Any other patients deemed unsuitable for the study at the discretion of the investigator

发起方

未提供